Key result
Western patients with hypertrophic cardiomyopathy experienced significantly higher disease-related mortality than Japanese patients (22.2% vs 4.4%; p<0.05) despite similar morphological features.
Why the study?
Does prognosis and morphology in hypertrophic cardiomyopathy differ between Japanese and Western patients?
Cohort (n=90)
Yes
Does prognosis and morphology in hypertrophic cardiomyopathy differ between Japanese and Western patients?
Absolute Event Rate: 22.2% vs 4.4%
p-value: p=< 0.05
Western patients with hypertrophic cardiomyopathy have a worse prognosis regarding disease-related mortality compared to Japanese patients, despite similar clinical and morphological features.
May warrant ethnicity-informed HCM risk assessment; leaves open causal mechanisms in this observational comparison.
Apical hypertrophic cardiomyopathy appears to be more common in Japan than in the West. Explanations for this difference include variable methods and criteria for the diagnosis. To assess morphological, clinical, and prognostic differences, 45 consecutive Japanese and 45 age- and gender-matched Western patients with hypertrophic cardiomyopathy were evaluated in two referral institutions by the same individuals. The diagnosis of hypertrophic cardiomyopathy was based on the echocardiographic demonstration of unexplained left ventricular hypertrophy. Patients were aged 8 to 64 years (mean 50); there were 66 males and 24 females. The pattern of left ventricular hypertrophy was similar in Japanese and Western patients: asymmetric septal 64 vs. 76%, concentric 22 vs. 13%, and apical 13 vs. 11% (p = NS). The incidence of an echocardiographic or Doppler calculated left ventricular gradient of > 30 mmHg was similar (11 vs. 18%; p = NS). The maximal left ventricular wall thickness was greater in Western patients (23 +/- 7 vs. 20 +/- 4 mm; p = 0.03), but was not different when adjusted for body surface area. Clinical features including incidence of family history and ventricular tachycardia during 24-h ambulatory electrocardiography were similar. During follow-up (4.9 +/- 4.0 years for Western vs. 4.4 +/- 2.0 years for Japanese), disease-related mortality was worse in Western patients (p < 0.05; 10 versus 2 patients). This evaluation, using the same diagnostic methods and criteria, reveals a worse prognosis in Western patients despite a similar clinical and morphological spectrum of hypertrophic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Chikamori et al. (1992) conducted a cohort in Hypertrophic cardiomyopathy (n=90). Western patients vs. Japanese patients was evaluated on Disease-related mortality (p=< 0.05). Western patients with hypertrophic cardiomyopathy experienced significantly higher disease-related mortality than Japanese patients (22.2% vs 4.4%; p<0.05) despite similar morphological features.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: